FACT Announces 2018 Fourth and 2019 First Quarter Accreditations; Accredited Entities Now Total 292

During the fourth quarter of 2018 and first quarter of 2019, 40 entities received accreditation from the Foundation for the Accreditation of Cellular Therapy:

- Cellular Therapy Initial Accreditation – 2
- Cord Blood Bank Initial Accreditation - 2
- Cellular Therapy Renewal Accreditation – 25
- Cord Blood Bank Renewal Accreditation - 11
- Total Accredited Cellular Therapy Entities – 236
- Total Accredited Cord Blood Banks – 56
- Number of Countries – 7
- Number of Countries – 24
- Additional Cellular Therapy Applicants –5
- Additional Cord Blood Applicants - 3

FACT is a non-profit voluntary foundation for standard-setting, self-assessment, inspection, and accreditation of hematopoietic collection, processing, and transplantation; immune effector cellular therapy; cord blood banking; and regenerative medicine. It is jointly sponsored by the American Society for Transplantation and Cellular Therapy (ASTCT) and the International Society for Cell and Gene Therapy (ISCT). WMDA-NetCord co-publishes cord blood standards.

For a complete list of accredited facilities and additional information about FACT accreditation, visit the FACT website.

The cellular therapy accreditation actions were:

**NEW CELLULAR THERAPY ACCREDITATIONS**

*Adult allogeneic and autologous hematopoietic progenitor cell transplantation; immune effector cellular therapy; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:*

- Fiona Stanley Hospital Blood and Marrow Transplant Program, Perth, Western Australia, Australia
  Program Director: Duncan Purtill, MBBS, FRACP, FRCPA

*Cellular therapy product processing with more than minimal manipulation under the FACT Common Standards:*

- Children’s GMP, LLC, Memphis, Tennessee, USA
  Program Director: Timothy Lockey, PhD

**CELLULAR THERAPY ACCREDITATION RENEWALS**

*Adult and pediatric allogeneic and autologous hematopoietic progenitor cell transplantation; immune effector cellular therapy; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal and more than minimal manipulation:*

- National University Health System Hematopoietic Progenitor Cell Transplantation Program, Singapore
  Program Director: Tan Lip Kun, MB ChB, MRCP, MRC Path

- The University of Utah Blood and Marrow Transplant Program, Salt Lake City, Utah, USA
  Program Director: Daniel Couriel, MD

*Adult and pediatric allogeneic and autologous hematopoietic progenitor cell transplantation; immune effector cellular therapy; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:*

- Barbara Ann Karmanos Cancer Center Blood and Marrow Stem Cell Transplant Program, Detroit, Michigan, USA
  Program Director: Joseph Uberti, MD, PhD
• Blood and Marrow Transplant Program at Medical City Dallas, Dallas, Texas, USA
  Program Director: Vikas Bhushan, MD

• Hackensack University Medical Center Blood and Marrow Transplantation Program, Hackensack, New Jersey, USA
  Program Directors: Michele Donato, MD and Alfred Gillio, MD

• Stem Cell Transplant Program at Barnes-Jewish Hospital and St. Louis Children’s Hospital at Washington University School of Medicine, St. Louis, Missouri, USA
  Program Director: Peter Westervelt, MD, PhD

• UF Health Shands Hospital, Gainesville, Florida, USA
  Program Director: John Wingard, MD

**Adult and pediatric allogeneic and autologous hematopoietic progenitor cell transplantation; immune effector cellular therapy; bone marrow (pediatric only) and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:**

• Montefiore Medical Center Bone Marrow and Stem Cell Transplantation Program, Bronx, New York, USA
  Program Director: Ira Braunschweig, MD

**Adult and pediatric allogeneic and autologous hematopoietic progenitor cell transplantation; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:**

• Alberta Blood and Marrow Transplant Program: Foothills Medical Centre, Alberta Children’s Hospital, Tom Baker Cancer Centre, and Calgary Laboratory Services, Calgary, Alberta, Canada
  Program Director: Andrew Daly, MD

• Hospital Israelita Albert Einstein, Morumbi, São Paulo, Brazil
  Program Director: Nelson Hamerschlag, MD

• Medical University of South Carolina Blood and Marrow Transplant Program, Charleston, South Carolina, USA
  Program Director: Robert Stuart, MD

• Saint Louis University Blood and Marrow Transplant Program, St. Louis, Missouri, USA
  Program Directors: Mark Fesler, MD and William Ferguson, MD

• University of Louisville Blood and Marrow Transplant Program, Louisville, Kentucky, USA
  Program Director: William W. Tse, MD

**Adult allogeneic and autologous hematopoietic progenitor cell transplantation; immune effector cellular therapy; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal and more than minimal manipulation:**

• Dana-Farber Cancer Institute/Brigham and Women’s Hospital Adult Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, USA
  Program Director: Joseph Antin, MD

**Adult allogeneic and autologous hematopoietic progenitor cell transplantation; immune effector cellular therapy; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:**

• The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, USA
  Program Director: H. Kent Holland, MD

• Loyola Medicine Stem Cell Transplant Program, Maywood, Illinois, USA
  Program Director: Patrick Stiff, MD
Adult allogeneic and autologous hematopoietic progenitor cell transplantation; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:

- Advocate Lutheran General Hospital Hematopoietic Progenitor Cell Transplant Program, Park Ridge, Illinois, USA
  Program Director: Tulio Rodriguez, MD
- Christchurch Hospital, Christchurch, Canterbury, New Zealand
  Program Director: Andrew Butler, MD

Adult autologous hematopoietic progenitor cell transplantation; peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:

- Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Pediatric Stem Cell Transplantation Program, Boston, Massachusetts, USA
  Program Director: Leslie Lehmann, MD
- Lahey Hospital and Medical Center Autologous Stem Cell Transplant Program, Burlington, Massachusetts, USA
  Program Director: Arthur Rabinowitz, MD
- Marshfield Clinic, Marshfield Medical Center Hematopoietic Progenitor Cell Transplant Program, Marshfield, Wisconsin, USA
  Program Director: Arlene Gayle, MD

Pediatric allogeneic and autologous hematopoietic progenitor cell transplantation; bone marrow and peripheral blood cellular therapy product collection; and cellular therapy product processing with minimal manipulation:

- The Royal Children’s Hospital Children’s Cancer Centre, Haemopoietic Stem Cell Transplant Programme, Parkville, Victoria, Australia
  Program Director: Françoise Méchinaud, MD, FRACP

Peripheral blood cellular therapy product collection

- American Red Cross, Carolinas Region
  Program Director: Corinne Goldberg, MD

Cellular therapy product processing with minimal and more than minimal manipulation:

- Dana-Farber Cancer Institute / Cell Manipulation Core Facility
  Program Director: Jerome Ritz, MD

Cellular therapy product processing with more than minimal manipulation:

- UTHealth – The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, Houston, Texas, USA
  Program Director: Fabio Triolo, PhD

The cord blood bank accreditation actions were:

NEW CORD BLOOD BANK ACCREDITATIONS

Cord blood collection, banking, and release for administration of unrelated donations:

- Canadian Blood Services’ Cord Blood Bank, Ottawa, Ontario, Canada
  Program Director: Heidi Elmoazzen, PhD
Cord blood collection, banking, and release for administration of related donations:

- HealthBaby Biotech (HK) Co., Ltd., Shatin, Hong Kong
  Program Director: Ki Wai Chik, MBChB

CORD BLOOD BANK ACCREDITATION RENEWALS

Cord blood collection, banking, and release for administration of unrelated and related donations:

- Cord Blood Bank of Ankara, Ankara, Turkey
  Program Director: Meral Beksaç, MD

- Institut Jules Bordet – ULB Cord Blood Bank, Bruxelles, Belgium
  Program Director: Dominique Bron, MD, PhD

- King Abdullah International Medical Research Center Cord Blood Bank, Riyadh, Saudi Arabia
  Program Director: Dunia Jawdat, PhD

- Leuvense Navelstrengbloedbank (Cord Blood Bank Leuven – Belgium), Leuven, Belgium
  Program Director: Timothy Devos, MD, PhD

- Liège Cord Blood Bank, Liège, Belgium
  Program Director: Yves Beguin, MD, PhD

- M. D. Anderson Cord Blood Bank, Houston, Texas, USA
  Program Director: Elizabeth J. Shpall, MD

- Sanquin Cord Blood Bank, Leiden, Netherlands
  Program Director: Daphne Thijssen-Timmer, PhD

- Treviso Cord Blood Bank, Treviso, Italy
  Program Director: Sergio De Angeli, PhD

Cord blood collection, banking, and release for administration of unrelated donations:

- Hong Kong Red Cross Catherine Chow Cord Blood Bank, Yaumatei, Hong Kong
  Program Director: Cheuk-Kwong Lee, MD

- Sheba Cord Blood Bank, Tel Hashomer, Israel
  Program Director: Amon Nagler, MD

Cord blood collection, banking, and release for administration of related donations:

- Cordlife Group Limited, Singapore
  Program Director: Arvin Faundo, MD